AUTHORS
Paresh Vyas, MD, PhD, Jessica Kaplan Altman, MD2, Alexander Joseph Ambinder, MD, MPH3, Jessica Ernest4, Kateryna Fedorov, MD5, Chaofeng Liu, PhD6, Yaara Ofir-Rosenfeld7, Alexander E. Perl, MD8, Archita Shrivastava9, Andrew Sochacki, MD10, Maximilian Stahl, MD11, Anthony Selwyn Stein, MD12, Robert Willis13, Erkut Bahceci, MD14, Naval Daver, MD15
AFFILIATIONS
1 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
2 Northwestern University, Chicago, United States, Robert H. Lurie Cancer Center, Chicago, United States
3 Johns Hopkins University School of Medicine, Baltimore, United States
4 Charm Therapeutics, London, United Kingdom
5 Vanderbilt University Medical Center, Nashville, United States
6 Charm Therapeutics, London, United Kingdom
7 Charm Therapeutics, London, United Kingdom
8 Abramson Cancer Center of the University of Pennsylvania, Philadelphia, United States
9 Charm Therapeutics, London, United Kingdom
10 START Midwest, Grand Rapids, United States
11 Yale Comprehensive Cancer Center, New Haven, United States, Yale University School of Medicine, New Haven, United States
12 City of Hope National Medical Center, Duarte, United States
13 Charm Therapeutics, London, United Kingdom
14 Charm Therapeutics, London, United Kingdom
15 MD Anderson Cancer Center, Houston, United States
ABSTRACT
Background and Significance:
Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy with poor outcomes in the relapsed or refractory (R/R) setting despite recent therapeutic advances. AML with NPM1 mutations or KMT2A or NUP98 rearrangements (KMT2Ar/NUP98r) represent key molecularly defined subtypes that depend on the menin–KMT2A transcriptional complex to maintain leukemogenic transcriptional programs and block myeloid differentiation (Grembecka et al., 2012; Kühn et al., 2016; Heikamp et al., 2022).
Clinical studies have established menin inhibition as an effective targeted therapeutic strategy for patients with R/R AML with KMT2Ar or NPM1 mutations (Issa et al., 2023; Arellano et al., 2025; Wang et al., 2025). However, acquired MEN1 mutations are an important resistance mechanism to first-generation menin inhibitors in both clinical studies, resulting in a short duration of response, and preclinical models (Perner et al., 2023; Bourgeois et al., 2026). Recurrent resistance variants, including S160T/C, M327I/V, G331R, E368V, and T349M, preserve the menin–KMT2A interaction while impairing inhibitor binding, ultimately leading to treatment resistance and disease relapse (Perner et al., 2023; Bourgeois et al., 2026). These findings highlight the need for next-generation menin inhibitors capable of retaining activity against clinically relevant acquired MEN1 resistance mutations.
CHM-029 is a potent, orally bioavailable, selective next-generation small-molecule menin inhibitor engineered to retain potency against clinically observed acquired MEN1 resistance variants. In vitro, CHM-029 demonstrated strong potency against wild-type (wt) menin and retained potency against all clinically reported acquired MEN1 resistance variants. In vivo, CHM-029 demonstrated tumor regressions in mouse models with either MEN1wt or MEN1M327I tumors, together with a dose dependent transcriptional modulation of menin-KMT2A target genes such as MEIS1. Importantly, no MEN1 mutations or other resistance mechanisms were observed in an in vitro forced drug-induced resistance study.
These findings support clinical evaluation of CHM-029 in patients with R/R AML with NPM1 mutations or KMT2A or NUP98 rearrangements.
Study Design and Methods:
This is an open-label, multicenter, global, first-in-human phase 1/2 study evaluating CHM-029 monotherapy in adults (≥18 years) with relapsed or refractory AML with NPM1 mutations or KMT2Ar or NUP98r and ECOG performance status ≤2 (Study NCT07751991). Prior treatment can include all standard therapies for AML, including prior menin inhibitors. Dose escalation uses a Bayesian Optimal Interval (BOIN) design with backfilling to evaluate safety and tolerability and identify the maximum tolerated dose (MTD) and/or optimal biological dose (OBD). Dose levels that satisfy protocol-defined escalation criteria and demonstrate preliminary clinical activity may be expanded through backfilling, enrolling up to 20 additional patients to further evaluate safety, pharmacokinetics, pharmacodynamics, and antileukemic activity. CHM-029 is administered orally, twice daily, in continuous 28-day cycles, until either disease progression or unacceptable toxicity. A future planned Phase 2 component will incorporate Backfill Adaptive Randomized Dose-optimization (BARD) to support optimal biological dose selection.
The primary objective is to evaluate the safety and tolerability of CHM-029 and determine the MTD and/or OBD. Primary endpoints include adverse events, dose-limiting toxicities, and determination of the MTD and/or OBD. Secondary endpoints include pharmacokinetics and preliminary antileukemic activity, including complete remission-based response rates, duration of response, event-free survival, and overall survival.
The trial is actively enrolling with accrual planned in the United States, United Kingdom and Europe.
DISCLOSURES
Paresh Vyas, MD, PhD: Yellowstone Biosciences - Current equity holder in private company; Charm Therapeutics - Honoraria; Abbvie - Honoraria; Servier - Honoraria; Syndax - Honoraria; Astellas - Honoraria; BMS - Research Funding; Yellowstone Biosciences - Research Funding; IMU Biosciences - Consultancy (Includes expert testimony); Yellowstone Biosciences - Current Employment